Verrica Pharmaceuticals Inc.
Clinical trials sponsored by Verrica Pharmaceuticals Inc., explained in plain language.
Dermatology company developing treatments for skin conditions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a blister beetle extract banish common warts? phase 3 trial investigates Results expected May 2027 (estimated) 🚀 Make-or-break
- New gel could zap away common warts in just weeks Results expected Jun 2027 (estimated) 🚀 Make-or-break
-
Can a blister beetle extract banish common warts? phase 3 trial investigates
Disease control Recruiting nowThis Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the act…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New gel could zap away common warts in just weeks
Disease control Recruiting nowThis study tests a gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older with at least one wart will apply the gel or a fake version. The goal is to see if the gel can clear all warts by day 84.
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC